Pancreatic Cancer Research

ResearcherPolish Academy of SciencesNo recent work listed

Marek Durlik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1905-6114; OpenAlex author ID A5019593251. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 2 papers

Papers 13

  1. Impact of COVID-19 on pancreatic cancer surgery: A high-volume Polish center experience. Last author DOI 10.17219/acem/144134↗
  2. Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes. Co-author DOI 10.3390/cancers14122840↗
  3. Clinical value of tissue DNA integrity index in pancreatic cancer. Last author DOI 10.1016/j.surge.2019.10.008↗
  4. Is mitochondrial DNA copy number a good prognostic marker in resectable pancreatic cancer? Last author DOI 10.1016/j.pan.2018.11.009↗
  5. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Co-author DOI 10.5114/pg.2019.83422↗
  6. Correlation of TNF-α and TGF-β polymorphisms with protein levels in pancreatic ductal adenocarcinoma and colorectal cancer. Last author DOI 10.5114/wo.2019.91537↗
  7. Opioid Tripeptides Hybridized with trans-1-Cinnamylpiperazine as Proliferation Inhibitors of Pancreatic Cancer Cells in Two- and Three-Dimensional in vitro Mod… Co-author DOI 10.1002/cmdc.201700453↗
  8. An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.15323↗
  9. The Q705K and F359L Single-Nucleotide Polymorphisms of NOD-Like Receptor Signaling Pathway: Association with Chronic Pancreatitis, Pancreatic Cancer, and Perio… Co-author DOI 10.1007/s00005-015-0355-9↗
  10. Ploidy and DNA index as prognostic factors in resected pancreatic ductal adenocarcinoma - a review of the literature. Co-author DOI 10.5114/pg.2014.47892↗
  11. Microenvironment elements involved in the development of pancreatic cancer tumor. Last author DOI 10.1155/2012/585674↗
  12. Metalloproteinase 2 and 9 activity in the development of pancreatic cancer. Co-author DOI 10.2478/v10035-012-0064-6↗
  13. Analysis of pancreatic cancer microenvironment: role of macrophage infiltrates and growth factors expression. Last author DOI 10.7150/jca.4537↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia Tuchalska-Czuroń · 3 shared papers, 2014–2020 · strength 0.39
  2. Agnieszka K. Sarnecka · 2 shared papers, 2016–2019 · strength 0.22
  3. Małgorzata Zagozda · 2 shared papers, 2016–2019 · strength 0.22
  4. Karolina Kędzierska-Kapuza · 1 shared paper, 2022 · strength 0.20
  5. Katarzyna Gardian · 3 shared papers, 2012 · strength 0.16
  6. Marta Magdalena Fudalej · 1 shared paper, 2022 · strength 0.15
  7. Anna Maria Badowska-Kozakiewicz · 1 shared paper, 2022 · strength 0.15
  8. Daria Kwaśniewska · 1 shared paper, 2022 · strength 0.15
  9. Andrzej Deptała · 1 shared paper, 2022 · strength 0.15
  10. Katarzyna Winter · 1 shared paper, 2019 · strength 0.08
  11. Stanisław Głuszek · 1 shared paper, 2019 · strength 0.08
  12. Anita Gąsiorowska · 1 shared paper, 2019 · strength 0.08
  13. Janusz Strzelczyk · 1 shared paper, 2019 · strength 0.08
  14. Renata Talar‐Wojnarowska · 1 shared paper, 2019 · strength 0.08
  15. Paweł Lampe · 1 shared paper, 2019 · strength 0.08
  16. Ewa I. Malecka-Panas · 1 shared paper, 2019 · strength 0.08
  17. A Dâbrowski · 1 shared paper, 2019 · strength 0.08
  18. Aleksandra Misicka · 1 shared paper, 2017 · strength 0.07
  19. Anna Katarzyna Laskowska · 1 shared paper, 2017 · strength 0.07
  20. Renata Górska · 1 shared paper, 2015 · strength 0.06
  21. Andrzej Miśkiewicz · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.